Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Kerecis completes Lipid Collagen Matrix first human clinical trial

Kerecis, a manufacturer of tissue-regeneration materials, has completed the first human clinical trial of its MariGen Lipid Collagen Matrix.

The MariGen Lipid Collagen Matrix is a marine-derived tissue regeneration product containing intact collagen and fish skin derived – Omega 3 oils to treat chronic wounds and for abdominal wall reconstruction.

The trial enrolled 10 patients with serious non-healing wounds and made their treatment with the MariGen matrix for 28 days.

Kerecis MD Baldur Tumi Baldursson said the results of the study demonstrate the safety of the MariGen Lipid Collagen Matrix technology and indicate the efficacy of the product.

"By the end of the study all 10 wounds had improved, with six completely healing," Baldursson said.

Kerecis Clinical R&D director Hilmar Kjartansson said their next step is a multi-center efficacy study with more patients.

"We are currently working on establishing partnerships with clinicians in the US, Europe and Australia to partner with us in such a trial," Kjartansson said.